

## Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone–releasing factor in patients with HIV. *N Engl J Med* 2007;357:2359-70.

Supplemental Table 1. Patients Discontinuing with Treatment Emergent Adverse Events

Placebo	Adverse Event(s)
	Headaches*
	Pain in Hands*
	Bilateral Joint Pain*
	Occasional Elevated Blood Pressure
Tesamorelin	
	Rash*
	Fatigue, Headache*
	Loss of Mobility of Lower Limbs and Arms*
	Allergic Reaction*
	Arthralgias*
	Abdominal Rash*
	Joint Swelling*
	Arthralgia and Pain in Right Knee*
	Periorbital and Bilateral Hand Swelling*
	Joint Pain
	Congestive Heart failure
	Joint Pain*
	Hyperglycemia
	Myalgia
	Rectal Cancer
	Swelling of Extremities, Joint Pain in Feet, Hands, Paresthesias of Hands and Feet*
	Abdominal Abscess, Possible Sepsis, Dehydration*
	Numbness in Hands*
	Constipation
	Injection Site Itchiness, Facial and Upper Body Redness*
	Diarrhea*
	Intermittent Muscle Pain*
	Carpal Tunnel Syndrome*
	Left Breast Enlargement*
	Numbness in Hands*
	Benign Prostatic Hypertrophy
	Hives*
	Hives*
	Redness and Itching at Injection Site*
	Pain in Fingers, Hands and Hips, Hypertension*
	Injection Site reaction
	Neuropathy, Anxiety*
	Carpal Tunnel Syndrome*

\* Patients classified as non-completers and discontinued due to an adverse event

Supplemental Table 2.

Effects of Antibodies to Tesamorelin on Changes in Visceral Adipose Tissue

Parameter	Statistic	Antibodies	
		Positive	Negative
Number of Patients	N	121	142
Visceral adipose tissue (cm <sup>2</sup> )			
Baseline	n	120	142
	Mean	176	180
	SD	69.9	82.9
Week 26 Actual	n	121	142
	Mean	144	154
	SD	70.0	77.0
Week 26 Percent Change (%)	n	120	142
	Mean	-18.2	-13.7
	SD	21.4	20.5
	p-value for antibodies <sup>1</sup>	0.07	
	p-value for baseline-by-antibodies interaction <sup>2</sup>	0.61	

Note: VAT – Visceral Adipose Tissue

<sup>1</sup> p-value from ANCOVA on the natural log ratio of VAT to baseline VAT. The model includes the natural log of baseline VAT and the antibodies effect.

<sup>2</sup> p-value from ANCOVA on the natural log ratio of VAT to baseline VAT. The model includes the natural log of baseline VAT, the antibodies effect and the natural log of baseline VAT by antibodies interaction.

Effects of Antibodies to Tesamorelin on Changes in IGF-I

Parameter	Statistic	Antibodies	
		Positive	Negative
Number of Patients	N	121	142
IGF-I Serum (ng/mL)			
Baseline	n	119	140
	Mean	163	162
	SD	58.6	60.7
Week 26 Actual	n	121	142
	Mean	273	278
	SD	123	122
Week 26 Change from Baseline	n	119	140
	Mean	109	116
	SD	115	112
	p-value for antibodies <sup>1</sup>	0.67	
	p-value for baseline-by-antibodies interaction <sup>2</sup>	0.88	

<sup>1</sup> p-value from ANCOVA on the IGF-I change from baseline. The model includes the baseline IGF-I and the antibodies effect.

<sup>2</sup> p-value from ANCOVA on the IGF-I change from baseline. The model includes the baseline IGF-I, the antibodies effect and the baseline IGF-I by antibodies interaction.